Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26 Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models Stevenage, UK, 24 August 2026 – NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-08-24 09:01:082026-09-14 09:02:17NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS
Stevenage, UK, 3 August 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026. A recognized leader in neuroscience drug development with particular expertise […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-08-03 08:59:232026-09-14 09:03:21NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer
Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-08 08:00:382026-07-31 12:02:19NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
Stevenage, UK, 1 December 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO). In his role at NRG, Paul will be project lead for NRG5051 which […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-12-01 08:00:502026-07-31 12:02:23NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS
Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26 Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models Stevenage, UK, 24 August 2026 – NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience […]
NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer
Stevenage, UK, 3 August 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026. A recognized leader in neuroscience drug development with particular expertise […]
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a […]
NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
Stevenage, UK, 1 December 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO). In his role at NRG, Paul will be project lead for NRG5051 which […]